This webinar will discuss the impact of alcohol, cocaine, and amphetamine use during the COVID-19 pandemic. It will review the physiological effects of substance use disorders (SUD) and heightened susceptibility to COVID-19, and discuss the impact on the African American population. This session will also cover recent increases in alcohol sales and consumption, discuss available treatment options for SUD, and review myths about alcohol during the current pandemic.
Michael Ingram, M.D. has worked in the field of psychiatry more than 25 years. He is a Past President of the Black Psychiatrists of America, and the current Director of Behavioral Health at Great Lakes Bay Health Care. He is the former Medical Director of the Behavioral Unit at McLaren Bay Psychiatric Associates. He graduated from Michigan State University, where he received both a Bachelor’s degree in Microbiology and his Medical degree from the College of Human Medicine. Dr. Ingram completed his residency training in Psychiatry at Lafayette Clinic and Wayne State University. He is board-certified in psychiatry. Dr. Ingram was recertified by the American Board of Psychiatry and Neurology in 2009, and accepted as a Fellow of the American Psychiatric Association (FAPA) in 2016. He is also a former Vice President of Michigan Psychiatric and Behavioral Associates, one of the largest medical groups north of metropolitan Detroit.
- Describe the effects of COVID-19 on alcohol, amphetamine, and cocaine on the body
- Specify the impact of COVID-19 on incidence of alcohol use
- Discuss the risk factors for alcohol, amphetamine, and cocaine in the African American population
- Discuss fact vs. fiction of alcohol, amphetamine, and cocaine use disorders
- Summarize treatment options for alcohol, amphetamine, and cocaine use disorders
Who Should Attend?
Clinicians, caseworkers, peer recovery support staff, administrators, and others who work on behalf of adults with serious mental illnesses and or co-occurring substance use disorders impacted by COVID-19.
Certificates of attendance will be available to viewers of 50% (30 minutes) or more of the live webinar (via email within 30 business days post-event). CEUs are not offered for this session. Webinar slide presentations and recordings will be posted to the website.